178 related articles for article (PubMed ID: 7552990)
21. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit.
Yeh P; Dedieu JF; Orsini C; Vigne E; Denefle P; Perricaudet M
J Virol; 1996 Jan; 70(1):559-65. PubMed ID: 8523570
[TBL] [Abstract][Full Text] [Related]
22. A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus.
Cheshenko N; Krougliak N; Eisensmith RC; Krougliak VA
Gene Ther; 2001 Jun; 8(11):846-54. PubMed ID: 11423932
[TBL] [Abstract][Full Text] [Related]
23. Stable transduction of actively dividing cells via a novel adenoviral/episomal vector.
Leblois H; Roche C; Di Falco N; Orsini C; Yeh P; Perricaudet M
Mol Ther; 2000 Apr; 1(4):314-22. PubMed ID: 10933949
[TBL] [Abstract][Full Text] [Related]
24. Early region 4 modulates adenovirus DNA replication by two genetically separable mechanisms.
Medghalchi S; Padmanabhan R; Ketner G
Virology; 1997 Sep; 236(1):8-17. PubMed ID: 9299612
[TBL] [Abstract][Full Text] [Related]
25. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors.
Mizuguchi H; Kay MA
Hum Gene Ther; 1999 Aug; 10(12):2013-7. PubMed ID: 10466635
[TBL] [Abstract][Full Text] [Related]
26. Efficient adenovirus-mediated gene expression in malignant human plasma cells: relative lymphoid cell resistance.
Prince HM; Dessureault S; Gallinger S; Krajden M; Sutherland DR; Addison C; Zhang Y; Graham FL; Stewart AK
Exp Hematol; 1998 Jan; 26(1):27-36. PubMed ID: 9430511
[TBL] [Abstract][Full Text] [Related]
27. Protease-deleted adenovirus vectors and complementing cell lines: potential applications of single-round replication mutants for vaccination and gene therapy.
Oualikene W; Lamoureux L; Weber JM; Massie B
Hum Gene Ther; 2000 Jun; 11(9):1341-53. PubMed ID: 10890743
[TBL] [Abstract][Full Text] [Related]
28. A genetic selection method for the transfer of HSV-1 glycoprotein B mutations from plasmid to the viral genome: preliminary characterization of transdominance and entry kinetics of mutant viruses.
Desai P; Homa FL; Person S; Glorioso JC
Virology; 1994 Oct; 204(1):312-22. PubMed ID: 8091662
[TBL] [Abstract][Full Text] [Related]
29. Designing E1 deleted adenoviral vector by homologous recombination.
Zamani A; Ghannad MS
Iran Biomed J; 2007 Jul; 11(3):199-202. PubMed ID: 18051781
[TBL] [Abstract][Full Text] [Related]
30. A new vector system with inducible E2a cell line for production of higher titer and safer adenoviral vectors.
Zhou H; Beaudet AL
Virology; 2000 Sep; 275(2):348-57. PubMed ID: 10998335
[TBL] [Abstract][Full Text] [Related]
31. Adenovirus-mediated increase of exogenous and inhibition of endogenous fosB gene expression in cultured pulmonary arterial smooth muscle cells.
Lu CY; Giordano FJ; Rogers KC; Rothman A
J Mol Cell Cardiol; 1996 Aug; 28(8):1703-13. PubMed ID: 8877780
[TBL] [Abstract][Full Text] [Related]
32. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host.
Poller W; Schneider-Rasp S; Liebert U; Merklein F; Thalheimer P; Haack A; Schwaab R; Schmitt C; Brackmann HH
Gene Ther; 1996 Jun; 3(6):521-30. PubMed ID: 8789802
[TBL] [Abstract][Full Text] [Related]
33. Transgene amplification and persistence after delivery of retroviral vector and packaging functions with E1/E4-deleted adenoviruses.
Torrent C; Jullien C; Klatzmann D; Perricaudet M; Yeh P
Cancer Gene Ther; 2000 Aug; 7(8):1135-44. PubMed ID: 10975674
[TBL] [Abstract][Full Text] [Related]
34. Genome concatenation contributes to the late gene expression defect of an adenovirus E4 mutant.
Jayaram S; Bridge E
Virology; 2005 Nov; 342(2):286-96. PubMed ID: 16140353
[TBL] [Abstract][Full Text] [Related]
35. Transactivation of adenovirus E2-early promoter by E1A and E4 6/7 in the context of viral chromosome.
Swaminathan S; Thimmapaya B
J Mol Biol; 1996 May; 258(5):736-46. PubMed ID: 8637006
[TBL] [Abstract][Full Text] [Related]
36. Selective gene transfer into the liver of non-human primates with E1-deleted, E2A-defective, or E1-E4 deleted recombinant adenoviruses.
Raper SE; Haskal ZJ; Ye X; Pugh C; Furth EE; Gao GP; Wilson JM
Hum Gene Ther; 1998 Mar; 9(5):671-9. PubMed ID: 9551615
[TBL] [Abstract][Full Text] [Related]
37. An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors.
Catalucci D; Sporeno E; Cirillo A; Ciliberto G; Nicosia A; Colloca S
J Virol; 2005 May; 79(10):6400-9. PubMed ID: 15858023
[TBL] [Abstract][Full Text] [Related]
38. Increased duration of transgene expression in the lung with plasmid DNA vectors harboring adenovirus E4 open reading frame 3.
Yew NS; Marshall J; Przybylska M; Wysokenski DM; Ziegler RJ; Rafter PW; Li C; Armentano D; Cheng SH
Hum Gene Ther; 1999 Jul; 10(11):1833-43. PubMed ID: 10446923
[TBL] [Abstract][Full Text] [Related]
39. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted.
Lusky M; Christ M; Rittner K; Dieterle A; Dreyer D; Mourot B; Schultz H; Stoeckel F; Pavirani A; Mehtali M
J Virol; 1998 Mar; 72(3):2022-32. PubMed ID: 9499056
[TBL] [Abstract][Full Text] [Related]
40. Characterization of an adenovirus gene transfer vector containing an E4 deletion.
Armentano D; Sookdeo CC; Hehir KM; Gregory RJ; St George JA; Prince GA; Wadsworth SC; Smith AE
Hum Gene Ther; 1995 Oct; 6(10):1343-53. PubMed ID: 8590739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
